Trial Profile

Combination of Checkpoint Inhibitor and Radiotherapy for Recurrent Gastric Cancer After Initial Treatment With Standard Therapy (CIRCUIT)

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 25 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nivolumab (Primary)
Indications Gastric cancer
Focus Therapeutic Use
Acronyms CIRCUIT

Most Recent Events

07 Jul 2022 According to UMIN the status of the trial is completed, updated on 18th August' 2021 and NCT states that the trial status is unknown which was last updated on July 15, 2020. Hence, not adding unknown status comment. Please update when and where more information is available.
07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
18 Aug 2021 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com